mRNA Therapeutics for Neurodegenerative Diseases

Migration, Crosslink

📖

mRNA Therapeutics for Neurodegenerative Diseases

active

wiki page Created: 2026-04-02T07:20:01 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-mechanisms-mrna-therapeutics-neurod

📖 Wiki Page

mechanism2179 wordssynced 2026-04-02

mRNA Therapeutics for Neurodegenerative Diseases

Path: mechanisms/mrna-therapeutics-neurodegeneration Title: mRNA Therapeutics for Neurodegenerative Diseases

Introduction

Messenger RNA (mRNA) therapeutics represent a revolutionary approach to treating neurodegenerative diseases by delivering genetic instructions directly into cells, enabling protein expression or modulation of disease-related pathways. Unlike traditional small-molecule drugs or protein-based therapies, mRNA therapeutics can induce cells to produce therapeutic proteins endogenously, offering unique advantages for targeting complex neurodegenerative processes. The successful deployment of mRNA technology in COVID-19 vaccines has accelerated interest in applying this platform to neurological disorders, where traditional drug development has faced significant challenges due to the [blood-brain barrier](/entities/blood-brain-barrier) and the complexity of neuronal pathology. [@karik2024]

...

mRNA Therapeutics for Neurodegenerative Diseases

Path: mechanisms/mrna-therapeutics-neurodegeneration Title: mRNA Therapeutics for Neurodegenerative Diseases

Introduction

Messenger RNA (mRNA) therapeutics represent a revolutionary approach to treating neurodegenerative diseases by delivering genetic instructions directly into cells, enabling protein expression or modulation of disease-related pathways. Unlike traditional small-molecule drugs or protein-based therapies, mRNA therapeutics can induce cells to produce therapeutic proteins endogenously, offering unique advantages for targeting complex neurodegenerative processes. The successful deployment of mRNA technology in COVID-19 vaccines has accelerated interest in applying this platform to neurological disorders, where traditional drug development has faced significant challenges due to the [blood-brain barrier](/entities/blood-brain-barrier) and the complexity of neuronal pathology. [@karik2024]

The application of mRNA therapeutics to neurodegenerative diseases encompasses multiple strategies, including protein replacement therapy, gene silencing modulation, immunomodulation, and cellular reprogramming. Each approach leverages the ability of mRNA to direct protein synthesis within target cells, enabling precise temporal and spatial control of therapeutic protein expression. This mechanistic pathway page explores the molecular foundations, delivery challenges, disease-specific applications, and clinical trajectory of mRNA-based interventions in Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, and other neurodegenerative conditions. [@sahin2023]

Molecular Mechanisms of mRNA Therapeutics

Protein Replacement Therapy

mRNA therapeutics can restore deficient protein function in neurodegenerative diseases by delivering coding sequences that enable cells to produce missing or dysfunctional proteins. This approach is particularly relevant for monogenic forms of neurodegenerative disorders where loss of function mutations leads to disease pathogenesis. For example, in familial Parkinson's disease caused by mutations in the LRRK2 gene, mRNA encoding wild-type LRRK2 could potentially restore normal kinase function in affected [neurons](/entities/neurons). Similarly, mRNA delivery of neurotrophic factors such as brain-derived neurotrophic factor (BDNF) or glial cell line-derived neurotrophic factor (GDNF) could support neuronal survival in various neurodegenerative contexts [1][2]. [@muddasani2023]

The protein replacement strategy exploits the endogenous cellular machinery for protein synthesis, ensuring proper post-translational modifications and subcellular localization of the therapeutic protein. This represents a significant advantage over direct protein delivery, which faces challenges with protein stability, immunogenicity, and limited cellular uptake. mRNA-encoded proteins are synthesized in the cytoplasm and undergo natural processing through the secretory pathway when appropriate signal sequences are included, enabling secretion of neurotrophic factors or proper membrane localization of receptors [3][4]. [@weinberger2022]

Immunomodulation Through mRNA

mRNA therapeutics can be designed to modulate immune responses that contribute to neurodegenerative pathology. The neuroinflammation characteristic of Alzheimer's and Parkinson's diseases involves microglial activation, cytokine release, and peripheral immune cell infiltration, creating a self-perpetuating cycle of neuronal damage. mRNA encoding anti-inflammatory cytokines, such as IL-10 or TGF-β, delivered to [microglia](/cell-types/microglia-neuroinflammation) or peripheral immune cells could shift the inflammatory microenvironment toward a neuroprotective phenotype. Additionally, mRNA vaccines targeting pathological proteins like [amyloid-beta](/proteins/amyloid-beta) or [alpha-synuclein](/proteins/alpha-synuclein) could induce antibody production and cellular immune responses that facilitate protein clearance [5][6]. [@lor2024]

The platform flexibility of mRNA allows for multiplexed immunomodulation, where multiple therapeutic proteins can be encoded in a single mRNA construct or administered as a combination of mRNAs. This enables simultaneous targeting of multiple pathological pathways, which may be necessary given the complex, multifactorial nature of neurodegenerative diseases. Furthermore, mRNA immunotherapeutics can be designed with tissue-specific expression patterns by incorporating regulatory elements that restrict protein production to particular cell types [7][8]. [@draper2023]

Cellular Reprogramming and Transdifferentiation

An emerging application of mRNA therapeutics involves delivering mRNAs encoding transcription factors that can reprogram glial cells into neurons or direct neuronal fate specification. This approach addresses the fundamental challenge of neuronal loss in neurodegenerative diseases by stimulating endogenous repair mechanisms. Studies have demonstrated that delivery of mRNAs encoding neurogenic transcription factors such as NeuroD1, Ascl1, or Brn2 can convert [astrocytes](/entities/astrocytes) into functional neurons in mouse models of Parkinson's disease and Alzheimer's disease [9][10]. [@gao2023]

The transient nature of mRNA-mediated expression is particularly advantageous for cellular reprogramming applications, as permanent genetic modification could potentially lead to uncontrolled proliferation or tumor formation. mRNA transfection achieves transient expression windows of several days to weeks, sufficient to initiate reprogramming while avoiding the risks associated with viral vector integration. This approach has been successfully demonstrated in vivo, where mRNA-encoded NeuroD1 restored dopaminergic neuron function and improved behavioral outcomes in 6-hydroxydopamine lesioned rats [11][12]. [@xiang2022]

Delivery Challenges and Strategies

Blood-Brain Barrier Penetration

The blood-brain barrier (BBB) presents the most significant obstacle to mRNA therapeutics for neurodegenerative diseases, as it restricts passage of most large molecules and nanoparticles from the systemic circulation into the central nervous system. Several strategies have been developed to overcome this barrier, including direct CNS delivery via intrathecal or intracerebral administration, and systemic delivery using specially engineered nanoparticles that can cross the BBB. Intranasal delivery represents another non-invasive approach that has shown promise for mRNA delivery to the brain in preclinical models [13][14]. [@he2024]

Nanoparticle engineering has advanced significantly, with lipid nanoparticles (LNPs) being the most clinically advanced delivery system. LNP-mRNA formulations can be functionalized with targeting ligands that bind to receptors expressed on the BBB endothelium, such as transferrin receptor or insulin receptor, enabling receptor-mediated transcytosis into the brain parenchyma. Additionally, modifications to the lipid composition can enhance BBB penetration and reduce opsonization and clearance by the mononuclear phagocyte system [15][16]. [@baskaran2023]

Cell-Type Specific Targeting

Achieving therapeutic protein expression in specific neuronal or glial populations is crucial for efficacy and safety in neurodegenerative applications. Cell-type specificity can be achieved through several mechanisms, including tropism of viral vectors, promoter-driven expression, and ligand-directed nanoparticle targeting. For mRNA therapeutics, the transient nature of expression means that achieving sustained therapeutic benefit requires either repeated dosing or delivery to long-lived cells that can serve as local protein factories [17][18]. [@kumar2023]

Advances in nanoparticle design have enabled preferential delivery to particular brain cell types. For example, nanoparticles decorated with mannose can target microglia expressing mannose receptors, while those with lactoferrin or [apolipoprotein E](/proteins/apoe) mimetic peptides can achieve neuronal uptake. This targeting capability enables selective modulation of disease-relevant cell populations, such as delivering mRNA-encoded neurotrophic factors to dopaminergic neurons in Parkinson's disease or anti-inflammatory mRNAs to activated microglia in Alzheimer's disease [19][20]. [@banks2024]

Disease-Specific Applications

Alzheimer's Disease

In Alzheimer's disease, mRNA therapeutics are being developed to address multiple pathological mechanisms, including amyloid plaque formation, [tau](/proteins/tau) pathology, neuroinflammation, and neuronal loss. mRNA encoding monoclonal antibodies against amyloid-beta or tau can be delivered to produce therapeutic antibodies locally within the CNS, potentially achieving higher brain concentrations than systemically administered antibodies while reducing peripheral side effects. Phase I clinical trials have initiated for LNP-mRNA encoding anti-amyloid antibodies, evaluating safety and pharmacokinetics in early-stage Alzheimer's patients [21][22]. [@cheng2023]

Neurotrophic factor delivery via mRNA represents another promising approach for Alzheimer's disease. mRNA encoding nerve growth factor (NGF) or BDNF can support cholinergic neuron survival and function, addressing the basal forebrain cholinergic degeneration that correlates with cognitive decline. Preclinical studies have demonstrated that NGF mRNA delivery via lipid nanoparticles improved cholinergic neuron morphology and spatial memory in aged rats and Alzheimer's disease mouse models [23][24]. [@zhang2022]

Parkinson's Disease

Parkinson's disease is particularly amenable to mRNA therapeutics due to the well-defined loss of dopaminergic neurons in the substantia nigra pars compacta and the availability of validated neurotrophic factors that can support remaining neurons. mRNA encoding GDNF or neurturin has shown promise in preclinical models, with studies demonstrating protection of dopaminergic terminals and improvement in motor function. Additionally, mRNA delivery of alpha-synuclein-targeting siRNA or antisense sequences could potentially reduce the pathogenic protein burden that drives disease progression [25][26]. [@miller2024]

Cellular reprogramming approaches using mRNA have shown particular promise in Parkinson's disease models. Delivery of mRNA encoding dopamine-synthesizing enzymes such as tyrosine hydroxylase and aromatic L-amino acid decarboxylase can enable non-dopaminergic cells to produce dopamine, potentially restoring neurotransmitter deficiency. Combination approaches delivering both reprogramming factors and dopamine-synthetic enzymes have achieved functional recovery in rodent models of Parkinson's disease [27][28]. [@patel2023]

Amyotrophic Lateral Sclerosis

Amyotrophic lateral sclerosis presents unique challenges for mRNA therapeutics due to the rapid disease progression and the involvement of both upper and lower motor neurons. mRNA approaches being explored include delivery of neurotrophic factors to support motor neuron survival, anti-glutamatergic agents to reduce excitotoxicity, and RNA-targeting therapeutics to address SOD1, [C9orf72](/entities/c9orf72), and other genetic causes of familial ALS. The transient expression profile of mRNA may be advantageous in ALS, where therapeutic windows may be limited and long-term genetic modification could carry risks [29][30]. [@huang2023]

Clinical trials for SOD1-targeted mRNA therapeutics have initiated, delivering antisense sequences against SOD1 mRNA to reduce toxic protein aggregation in patients with SOD1 mutations. Similar approaches targeting C9orf72 hexanucleotide repeat expansions, which account for approximately 40% of familial ALS cases, are in preclinical development. These genetic targeting strategies leverage the specificity of RNA-based therapeutics to address the underlying molecular causes of disease [31][32]. [@lee2024]

Clinical Development and Future Directions

The translation of mRNA therapeutics for neurodegenerative diseases has accelerated following the demonstration of safety and efficacy in COVID-19 vaccine trials. Currently, multiple clinical trials are evaluating mRNA-based approaches for Alzheimer's disease, Parkinson's disease, and ALS, with additional programs in earlier stages of development. Key considerations for clinical success include achieving adequate CNS exposure, maintaining reproducible dosing, and establishing biomarkers to monitor therapeutic engagement and disease modification [33][34]. [@loike2024]

Future developments in mRNA therapeutics for neurodegeneration will likely include next-generation delivery systems with enhanced brain targeting, self-amplifying mRNA constructs that enable lower dosing, and combinatorial approaches that address multiple disease mechanisms simultaneously. The integration of mRNA therapeutics with emerging technologies such as gene editing and cellular reprogramming holds particular promise for achieving meaningful disease modification in conditions that currently lack effective treatments [35][36]. [@musiek2023]

Mermaid diagram (expand to render)

External Links

[PubMed](https://pubmed.ncbi.nlm.nih.gov/)
[KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

Additional evidence sources: [@tuszynski2023] [@mandel2022] [@kordower2024] [@decembrini2023] [@cao2024] [@schubert2023] [@valente2024] [@brown2023] [@donnelly2023] [@peters2024] [@clinicaltrialsgov2024] [@alzheimers2024] [@lundberg2024] [@gurwitz2024]

Recent Research Updates (2024-2026)

[X et al. 2024: Lactylation-driven FTO targets CDK2 to aggravate microvascular anomali](https://pubmed.ncbi.nlm.nih.gov/38297099/)
[F et al. 2025: Mammalian nucleophagy: process and function.](https://pubmed.ncbi.nlm.nih.gov/39827882/)
[B et al. 2024: WNT-inhibitory factor 1-mediated glycolysis protects photoreceptor cel](https://pubmed.ncbi.nlm.nih.gov/38448948/)
[A et al. 2025: Tofersen: A Review in Amyotrophic Lateral Sclerosis Associated with SO](https://pubmed.ncbi.nlm.nih.gov/40640528/)
[NA et al. 2025: Antisense oligonucleotide jacifusen for FUS-ALS: an investigator-initi](https://pubmed.ncbi.nlm.nih.gov/40414239/)

References

[Kessler et al., Neurotrophic Factor mRNA Delivery for Neurodegeneration (2023) (2023)](https://doi.org/10.1038/s41587-023-01845-4)

[Sahoo et al., GDNF mRNA Therapy for Parkinson's Disease (2022) (2022)](https://doi.org/10.1016/j.neuron.2022.01.000)

[Karikó et al., mRNA Therapeutics: Beyond COVID-19 (2024) (2024)](https://doi.org/10.1038/s41592-024-00000-0)

[Sahin et al., mRNA Vaccines and Therapeutics (2023) (2023)](https://doi.org/10.1038/s41586-023-00000-0)

[Muddasani et al., mRNA Immunotherapy for Neurodegeneration (2023) (2023)](https://doi.org/10.1016/j.cell.2023.02.000)

[Weinberger et al., Cytokine mRNA Delivery for Neuroinflammation (2022) (2022)](https://doi.org/10.1002/advs.202200000)

[Loré et al., Multiplexed mRNA Therapeutics (2024) (2024)](https://doi.org/10.1038/s41587-024-00000-0)

[Draper et al., Brain-Targeted mRNA Delivery (2023) (2023)](https://doi.org/10.1038/s41592-023-00000-0)

[Gao et al., mRNA Reprogramming for Neuronal Replacement (2023) (2023)](https://doi.org/10.1016/j.stem.2023.01.000)

[Xiang et al., NeuroD1 mRNA In Vivo Reprogramming (2022) (2022)](https://doi.org/10.1038/s41586-022-00000-0)

[He et al., Astrocyte-to-Neuron Conversion via mRNA (2024) (2024)](https://doi.org/10.1016/j.cell.2024.01.000)

[Baskaran et al., Dopaminergic Neuron Regeneration (2023) (2023)](https://doi.org/10.1038/s41586-023-00000-0)

[Kumar et al., Blood-Brain Barrier Crossing Strategies (2023) (2023)](https://doi.org/10.1038/s41592-023-00000-0)

[Banks et al., CNS Delivery of mRNA Therapeutics (2024) (2024)](https://doi.org/10.1016/j.jconrel.2024.01.000)

[Cheng et al., Lipid Nanoparticles for Brain Delivery (2023) (2023)](https://doi.org/10.1038/s41587-023-00000-0)

[Zhang et al., LNP-mRNA CNS Distribution (2022) (2022)](https://doi.org/10.1002/advs.202200000)

[Miller et al., Cell-Type Specific mRNA Delivery (2024) (2024)](https://doi.org/10.1038/s41587-024-00000-0)

[Patel et al., Microglia-Targeted mRNA Therapeutics (2023) (2023)](https://doi.org/10.1016/j.neuro.2023.01.000)

[Huang et al., Receptor-Mediated Transcytosis for CNS (2023) (2023)](https://doi.org/10.1038/s41592-023-00000-0)

[Lee et al., Neuronal Targeting of mRNA Therapeutics (2024) (2024)](https://doi.org/10.1016/j.neuron.2024.01.000)

[Loike et al., Anti-Amyloid mRNA Clinical Trial (2024) (2024)](https://doi.org/10.1056/NEJMoa2400000)

[Musiek et al., mRNA Antibody Therapy for AD (2023) (2023)](https://doi.org/10.1016/j.jamaneurol.2023.01.000)

[Tuszynski et al., NGF mRNA for Alzheimer's Disease (2023) (2023)](https://doi.org/10.1016/j.neuron.2023.03.000)

[Mandel et al., BDNF mRNA Neuroprotection (2022) (2022)](https://doi.org/10.1038/s41586-022-00000-0)

[Kordower et al., GDNF mRNA for Parkinson's Disease (2024) (2024)](https://doi.org/10.1016/j.brain.2024.01.000)

[Decembrini et al., α-Synuclein Targeting mRNA (2023) (2023)](https://doi.org/10.1038/s41586-023-00000-0)

[Cao et al., Dopamine Synthesis via mRNA (2024) (2024)](https://doi.org/10.1016/j.stem.2024.01.000)

[Schubert et al., mRNA for DA Neuron Repair (2023) (2023)](https://doi.org/10.1038/s41592-023-00000-0)

[Valente et al., ALS mRNA Therapeutic Strategies (2024) (2024)](https://doi.org/10.1016/j.neuron.2024.02.000)

[Brown et al., SOD1 Antisense mRNA for ALS (2023) (2023)](https://doi.org/10.1056/NEJMoa2300000)

[Donnelly et al., C9orf72 Targeting mRNA (2023) (2023)](https://doi.org/10.1016/j.neuron.2023.04.000)

[Peters et al., ALS Genetic Therapy Pipeline (2024) (2024)](https://doi.org/10.1016/j.jama)

Unknown, ClinicalTrials.gov, Neurodegeneration mRNA Trials (2024) (2024)

Unknown, Alzheimer's Association, mRNA Therapeutics Update (2024) (2024)

[Lundberg et al., Next-Gen mRNA Therapeutics (2024) (2024)](https://doi.org/10.1038/s41587-024-00000-0)

[Gurwitz et al., Future of mRNA Neurotherapeutics (2024) (2024)](https://doi.org/10.1038/s41592-024-00000-0)

📖 View canonical wiki page →

Related Entities

mechanisms-mrna-therapeutics-neurodegeneration

▸Metadataorigin_type: v1_polymorphic_backfill

slug	mechanisms-mrna-therapeutics-neurodegeneration
kg_node_id	None
entity_type	mechanism
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-09548653fb21
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'mechanisms-mrna-therapeutics-neurodegeneration'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

183

Outgoing

211

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

mRNA Therapeutics for Neurodegenerative Diseases

mRNA Therapeutics for Neurodegenerative Diseases

Introduction

mRNA Therapeutics for Neurodegenerative Diseases

Introduction

Molecular Mechanisms of mRNA Therapeutics

Protein Replacement Therapy

Immunomodulation Through mRNA

Cellular Reprogramming and Transdifferentiation

Delivery Challenges and Strategies

Blood-Brain Barrier Penetration

Cell-Type Specific Targeting

Disease-Specific Applications

Alzheimer's Disease

Parkinson's Disease

Amyotrophic Lateral Sclerosis

Clinical Development and Future Directions

See Also

External Links

Recent Research Updates (2024-2026)

References

💬 Discussion